Let's TalkLet's TalkA five-figure treatment decision made over months, which makes the follow-up sequence worth more than the campaign - most practices lose these cases in the gap between consult and financing.
Full-arch cases die in predictable places - between enquiry and consult, between consult and treatment plan, and between plan and financing approval. Send us 90 days of enquiries and outcomes and we will show you the drop-off at each stage, with the revenue attached to each gap.
Four failures we see repeatedly in this vertical, and what each one actually costs.
A full-arch case is a five-figure decision people research for months, often while saving for it. Most practices follow up for a few days and then mark the lead dead. The cases are not lost at the enquiry - they are lost in month two, when nobody was still in the conversation.
The patient wants the treatment and cannot pay for it this month. If financing is not introduced early, clearly and without embarrassment, the case stalls and the practice records it as a price objection. It was a cashflow objection, and it was solvable.
At these case values, a lead costing four times more that converts twice as often is comfortably the better lead. Practices optimising to cheap leads systematically buy the enquiries least likely to become cases, and the reporting tells them it is going well.
Implant consults take clinical time. Filling them with people who were price-shopping or not candidates costs more than the media did, so qualification has to happen before the appointment rather than during it.
The real deliverables, not a list written to make a proposal look thicker.
Where cases are lost between enquiry, consult, plan and financing, with revenue attached to each gap. This decides the order of everything else.
A sequence measured in months rather than days, with financing introduced early. This is usually where the largest recoverable revenue sits.
Pre-consult screening so clinical time is spent on candidates. Protects the thing that actually limits how many cases a practice can take.
Conversion moved as far down the funnel as your volume supports - accepted case where possible, qualified consult otherwise. Cheap leads stop being the target.
Budget follows cost per accepted case against treatment value. At full-arch values that number tolerates far more spend than a cost-per-lead target ever allowed.
A three-location dental group had no standard follow-up between sites and was measuring form fills. We standardised the funnel across locations, moved budget into Google Local Services Ads where it converted better, and put automated reminders behind every booking. Cost per lead fell to $19 and show-rate lifted 44% - and in implant dentistry the show-rate is the number that matters, because a consult that does not arrive is a five-figure case that never starts.
Read the full case studyWe were closing leads after five days. The audit showed most of our cases were deciding in month two, when we had already given up.
Bringing financing up early stopped most of what we had been recording as price objections.
Pre-qualifying before the consult gave me back clinical hours I was giving away to people who were never candidates.
Months, not days. A full-arch case is a five-figure decision people research and save for, and the practices winning these cases are still in the conversation in month two and month three. Most practices stop after a week and record the lead as dead, which is why the drop-off audit almost always finds the largest recoverable revenue in the nurture rather than in the media.
Because at these case values it inverts the decision. A lead costing four times more that converts at twice the rate is clearly better, but a cost-per-lead target rejects it. Optimising to cheap leads reliably buys the enquiries least likely to become cases while the dashboard reports improvement. We move the measure as far down the funnel as your volume supports - accepted case where there is enough data, qualified consult otherwise.
Introduced early and framed as the normal way these cases are paid for, rather than raised at the end as a rescue. Most stalled implant cases are cashflow objections recorded as price objections: the patient wants the treatment and cannot fund it this month. Putting financing into the nurture sequence rather than the closing conversation is one of the highest-return changes available.
Screening questions and, where appropriate, a short call before the appointment is confirmed - enough to tell a candidate from a price-shopper. Implant consults consume clinical time, which is the practice's real constraint, so filling them with non-candidates costs more than the media. It reduces booked consults and raises accepted cases, which looks wrong on a volume report and right on a revenue one.
Yes, and often better than for a group, because the follow-up is easier to run consistently when one team owns it. What matters is case value and clinical capacity: a practice doing full-arch work has the economics to support real acquisition spend. A practice doing mostly single implants at lower values needs a tighter cost per case, which is achievable but leaves less room.
Fewer than aesthetics, but they exist. Outcome promises, guarantees about longevity, and before-and-after imagery are all constrained - the last one on Meta specifically. Your state dental board also has rules on testimonials and on how credentials and specialty claims may be described, and those differ by state. We check both before creative is produced.
This is one part of a bigger service. Here is the whole of it, and the closest neighbours.
No pitch deck, no discovery call you have to sit through. Tell us the situation and we will tell you whether we can help.